ADAG Adagene Inc. ADRs
We are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Our platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by our immunotherapy pipeline. These features enable our novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. We have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.
$2.83 +0.01 (0.36%)
As of 05/23/2022 15:56:31 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: China
Country of incorporation:
IPO date: 02/09/2021
Outstanding shares: 43,794,078
Average volume: 19,670
Market cap: $125,032,093
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Annual filings: 20-F
Sedol:
Valuation (See tab for details)
PE ratio: -7.05
PB ratio: 0.79
PS ratio: 5.77
Return on equity: -18.41%
Net income %: -3,307.95%